A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

This study is testing whether adding tislelizumab (an immunotherapy drug) to standard pre-surgery chemotherapy (called FLOT) improves outcomes for people with resectable (surgically removable) cancer of the stomach, esophagus, or the junction between the two. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with locally advanced gastric, esophageal, or gastroesophageal junction cancer confirmed by tissue biopsy - Your cancer has not spread to distant organs (no metastases) - Your tumor is considered surgically removable - You are in good overall health and have not received prior treatment for this cancer **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body - You have previously received chemotherapy or immunotherapy for this cancer - You have active autoimmune disease or are on ongoing steroid treatment - You have significant heart, liver, kidney, or bone marrow problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.